https://www.marketscreener.com/quote/stock/KAMADA-LTD-23145606/news/Kamada-Submits-Proposed-Phase-3-Protocol-to-FDA-for-Inhaled-Alpha-1-Antitrypsin-for-Treatment-of-Alp-24787384/?utm_source=telegram&utm_medium=social&utm_campaign=share